Cargando…

Suvorexant improves intractable nocturnal enuresis by altering sleep architecture

Little is known about sleep-based approaches to the treatment of nocturnal enuresis (NE). This report is the first to describe the successful use of suvorexant, an orexin receptor antagonist, in a 12-year-old boy with intractable NE. With suvorexant, the frequency of NE gradually decreased from 14 o...

Descripción completa

Detalles Bibliográficos
Autor principal: Matsumoto, Tohru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970267/
https://www.ncbi.nlm.nih.gov/pubmed/33727289
http://dx.doi.org/10.1136/bcr-2020-239621
_version_ 1783666402316517376
author Matsumoto, Tohru
author_facet Matsumoto, Tohru
author_sort Matsumoto, Tohru
collection PubMed
description Little is known about sleep-based approaches to the treatment of nocturnal enuresis (NE). This report is the first to describe the successful use of suvorexant, an orexin receptor antagonist, in a 12-year-old boy with intractable NE. With suvorexant, the frequency of NE gradually decreased from 14 of 14 days (100%) to 5 of 14 days (35.7%). Sleep polysomnography indicated that rapid eye movement (REM) sleep increased from 101.5 min (19.9%) before suvorexant to 122.1 min (24.9%) with suvorexant. Furthermore, N2 increased from 233 min (45.6%) to 287.5 min (58.7%) during non-REM sleep. In contrast, N3 decreased from 160 min (31.3%) to 65 min (13.3%) during non-REM sleep. Suvorexant appeared to lighten the depth of sleep and alter sleep architecture. Although the application of an insomnia medication for treating NE seems paradoxical, suvorexant reduced the frequency of NE in patients with severe intractable NE. Thus, this treatment strategy warrants further examination.
format Online
Article
Text
id pubmed-7970267
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-79702672021-04-01 Suvorexant improves intractable nocturnal enuresis by altering sleep architecture Matsumoto, Tohru BMJ Case Rep Case Report Little is known about sleep-based approaches to the treatment of nocturnal enuresis (NE). This report is the first to describe the successful use of suvorexant, an orexin receptor antagonist, in a 12-year-old boy with intractable NE. With suvorexant, the frequency of NE gradually decreased from 14 of 14 days (100%) to 5 of 14 days (35.7%). Sleep polysomnography indicated that rapid eye movement (REM) sleep increased from 101.5 min (19.9%) before suvorexant to 122.1 min (24.9%) with suvorexant. Furthermore, N2 increased from 233 min (45.6%) to 287.5 min (58.7%) during non-REM sleep. In contrast, N3 decreased from 160 min (31.3%) to 65 min (13.3%) during non-REM sleep. Suvorexant appeared to lighten the depth of sleep and alter sleep architecture. Although the application of an insomnia medication for treating NE seems paradoxical, suvorexant reduced the frequency of NE in patients with severe intractable NE. Thus, this treatment strategy warrants further examination. BMJ Publishing Group 2021-03-16 /pmc/articles/PMC7970267/ /pubmed/33727289 http://dx.doi.org/10.1136/bcr-2020-239621 Text en © BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Case Report
Matsumoto, Tohru
Suvorexant improves intractable nocturnal enuresis by altering sleep architecture
title Suvorexant improves intractable nocturnal enuresis by altering sleep architecture
title_full Suvorexant improves intractable nocturnal enuresis by altering sleep architecture
title_fullStr Suvorexant improves intractable nocturnal enuresis by altering sleep architecture
title_full_unstemmed Suvorexant improves intractable nocturnal enuresis by altering sleep architecture
title_short Suvorexant improves intractable nocturnal enuresis by altering sleep architecture
title_sort suvorexant improves intractable nocturnal enuresis by altering sleep architecture
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970267/
https://www.ncbi.nlm.nih.gov/pubmed/33727289
http://dx.doi.org/10.1136/bcr-2020-239621
work_keys_str_mv AT matsumototohru suvorexantimprovesintractablenocturnalenuresisbyalteringsleeparchitecture